Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R2 ImageChecker Approval Launches CAD Lung Market; iCAD Preps To Join

This article was originally published in The Gray Sheet

Executive Summary

FDA approval of R2 Technology's ImageChecker CT CAD system for lung nodules July 8 provides the firm with a comfortable head-start over competitor iCAD, which expects to launch its own system in 2005

You may also be interested in...



CAD Firms Solidify Mammography Deals, Look To Lung Indication

R2 Technology and iCAD's agreements with imaging equipment players reflect a growing reliance on computer-aided detection for mammography screening

CAD Firms Solidify Mammography Deals, Look To Lung Indication

R2 Technology and iCAD's agreements with imaging equipment players reflect a growing reliance on computer-aided detection for mammography screening

Vital Images to use iCAD technology

iCAD's Second Look CT computer-aided detection (CAD) will be integrated, pending FDA approval, into the firm's Vitrea 2 medical imaging software for diagnostic evaluation of CT and MR image data to detect polyps that could lead to colon cancer under a non-exclusive agreement. Vital Images inked a July deal with CAD-competitor R2 Technology to incorporate the latter firm's ImageChecker CT system with Vitrea 2 for lung nodules (1"The Gray Sheet" July 19, 2004, p. 22). Vital Images is a distributor for R2...

Related Content

UsernamePublicRestriction

Register

MT020593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel